IMPACT OF COMBINATION THERAPY ON APOB/APOA1 RATIO AND CARDIOMETABOLIC PARAMETERS IN YOUNG PATIENTS WITH MAFLD AND SUBCLINICAL CARDIOVASCULAR DISEASE

Abstract

Metabolic dysfunction–associated fatty liver disease (MAFLD) represents a growing global health burden closely linked to obesity, insulin resistance, and early cardiovascular remodeling. Patients with MAFLD frequently demonstrate an atherogenic lipid profile characterized by an elevated ApoB/ApoA1 ratio. This biomarker reflects the balance between pro‑atherogenic and anti‑atherogenic lipoproteins and has been proposed as a superior predictor of cardiovascular risk compared to traditional lipid parameters. The present study evaluates the clinical impact of combination therapy including semaglutide on metabolic, hepatic, and vascular markers in high‑risk patients. Particular attention was paid to dynamic changes in insulin resistance and subclinical vascular alterations.

References

1. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I as risk indicators of coronary heart disease.
2. Emerging Risk Factors Collaboration. Lipoproteins and cardiovascular disease risk.
3. European Society of Cardiology Guidelines on dyslipidemia management.
4. American Diabetes Association. Standards of Medical Care in Diabetes.
5. Armstrong MJ et al. GLP‑1 receptor agonists in nonalcoholic fatty liver disease.
6. Younossi ZM et al. Global epidemiology of NAFLD/MAFLD.
7. Targher G et al. NAFLD and increased cardiovascular risk.
8. Ridker PM et al. Inflammation and atherosclerosis.
9. Bays HE et al. Obesity and cardiometabolic risk.
10. Grundy SM. Metabolic syndrome update.
11. Ference BA et al. LDL particles and atherosclerosis.
12. Marso SP et al. Cardiovascular outcomes with GLP‑1 receptor agonists.
13. Sattar N et al. Semaglutide and cardiovascular outcomes.
14. Byrne CD, Targher G. MAFLD pathophysiology.
15. Ballantyne CM et al. Apolipoproteins in clinical practice.
16. Bril F, Cusi K. Management of fatty liver disease.
17. Packer M. Metabolic effects of GLP‑1 therapy.
18. Toth PP et al. Residual cardiovascular risk.
19. Neeland IJ et al. Visceral adiposity and cardiometabolic disease.
20. Mach F et al. ESC prevention guidelines.